Agilent Technologies (A) is back in focus after two contrasting developments: the Supreme Court left rulings invalidating its CRISPR related patents in place, and the company introduced its new BioTek Cytation 9 cell imaging multimode reader.

At a share price of $120.39, investors have seen a 7.96% 1 month share price return and a 5.72% 7 day gain. However, the 90 day share price return of 17.50% and year to date share price return of 12.73% point to fading momentum despite a 1 year total shareholder return of 17.71%.

If the patent ruling and new product launch have you rethinking exposure to life sciences and diagnostics, it can be useful to compare Agilent with other healthcare related AI names through 34 healthcare AI stocks

With the stock at $120.39, trailing a 17.5% 90 day share price decline but sitting at about a 3% intrinsic discount and a 33% gap to analyst targets, is this a reset that opens a buying window, or is the market already pricing in future growth?

Most Popular Narrative: 26% Undervalued

At $120.39, the most followed narrative anchors Agilent's fair value around $161.94, implying a sizeable valuation gap that rests on specific growth and margin assumptions.

Strategic investments in higher margin recurring revenue streams, including consumables, software, services, and digital platforms, are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue growth, margin expansion, and earnings profile are built into that fair value and price target spread? The narrative outlines a detailed path for sales, profitability, and valuation multiples that may be different from what you might infer by only looking at recent share price moves.

Result: Fair Value of $161.94 (UNDERVALUED)

However, this depends on tariffs and supply chain costs not rising more than expected, and on capital equipment replacement cycles not slowing beyond what analysts currently anticipate.

Next Steps

With the mood split between patent setbacks and valuation upside, it helps to look at the underlying data yourself and decide quickly where you stand. To see what optimists are focusing on, review the 4 key rewards.

Ready for more investment ideas?

If Agilent has sharpened your focus, do not stop here. Widen your watchlist with a few targeted ideas that other investors could overlook.

• Target potential mispricings by scanning a curated list of value opportunities through the 57 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies that feature resilient payouts via the 12 dividend fortresses.
• Reduce unnecessary surprises by focusing on companies that score well on stability using the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.